Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12600388 | 1.00 | MAPK1 (0.33) | MAPK1CNR1CNR2L3MBTL1 | |
| SCHEMBL12371580 | 1.00 | MAPK1 (0.33) | MAPK1CNR1CNR2L3MBTL1 | |
| SCHEMBL7141048 | 0.91 | TLR4 (0.32) | — | |
| SCHEMBL12560742 | 0.91 | MAPK1 (0.42) | MAPK1CNR1CNR2L3MBTL1 | |
| SCHEMBL12371570 | 0.90 | TLR4 (0.34) | — | |
| SCHEMBL12601165 | 0.88 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL10042138 | 0.87 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL4204268 | 0.86 | TLR4 (0.37) | MAPK1CNR1CNR2 | |
| SCHEMBL7136453 | 0.83 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL7136442 | 0.83 | ASGR1 (0.33) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994154-B2 | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | Ersai R&D Management Co., Ltd. (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100227835-A1 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227835-A1 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA | LIPG, FUT6, UGCG | MAPK1 3870/4885CNR1 2713/4885CNR2 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.